Reuters - India's Torrent Pharmaceuticals Ltd. and Iceland's Actavis are among the top contenders for Merck KGaA's generics business, which could be sold for more than $6 billion, the Times of India reported on Tuesday.
Reuters - India's Torrent Pharmaceuticals Ltd. and Iceland's Actavis are among the top contenders for Merck KGaA's generics business, which could be sold for more than $6 billion, the Times of India reported on Tuesday.
No comments:
Post a Comment